Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:6:p6
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 6 (pt 6/36)
Character Range: 324392–327365

closure and compliant with the requirements of the required advisory statements for medicine labels; or

       (e) in preparations for dermal use containing 1% or less of cold pressed neem seed oil.
    AZAMETHIPHOS.
    AZOBENZENE.
BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2% or less of antibiotic substances.
    BARIUM SALTS except:

       (a) when included in Schedule 5; or

       (b) barium sulfate; or

       (c) in paints or tinters containing 5% or less of barium calculated on the non‑volatile content of the paint or tinter.
    BASIC BLUE 26 (CAS No. 2580‑56‑5) except when used as a colourant in cosmetics not intended to be in contact with mucous membranes.
    BASIC ORANGE 31 (2‑[(4‑aminophenyl)azo]‑1,3‑dimethyl‑1H‑imidazolium chloride) except:

       (a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or

       (b) in hair dye preparations containing 1% or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:

          (i) KEEP OUT OF REACH OF CHILDREN;

          (ii) IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

          (iii) WARNING – This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye;

        written in letters not less than 1.5 mm in height.
    BASIC RED 76 (CAS No. 68391‑30‑0) in non‑oxidative hair dye preparations and eyebrow/eyelash colouring products containing 2% or less of Basic Red 76 and 0.001% or less of free o‑anisidine.
    BAY OIL except:

       (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

       (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

       (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

          (i) KEEP OUT OF REACH OF CHILDREN; and

          (ii) NOT TO BE TAKEN; or

       (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

          (i) KEEP OUT OF REACH OF CHILDREN; and

          (ii) NOT TO BE TAKEN; or

       (e) in preparations containing 25% or